9th Annual Biomarkers Congress

View Profile


Speaking/Presenting-Abstract/Poster at Mtg

Topic Authors / presenters Event name Event date
1. A phase I study of gefitinib (Iressa) in combination with hypofractionated thoracic radiation therapy (HRT) with stereotactic body frame (SBF) immobilization in patients with advanced non-small cell lung cancer (NSCLC). European Society of Medical Oncology/International Association for the Study of Lung Cancer January, 2008
2. Evaluation of a deformable re-contouring method for adaptive therapy. ACRO January, 2008
3. Molecular markers in head and neck cancer: p16 and vascular endothelial growth factor predict for improved outcomes following treatment 7th International Conference on Head and Neck Cancer January, 2008
4. Quantification of anatomic positional variation and movement over the course of external beam radiation 7th International Conference on Head and Neck Cancer January, 2008
5. Daily image guidance for intensity modulated radiation therapy (IMRT) for head and neck cancer 7th International Conference on Head and Neck Cancer January, 2008
6. Pilot study of carboplatin/radiotherapy plus 'dose-dense' pemetrexed for locally advanced non-small cell lung carcinoma ASCO January, 2008
7. Phase I trial of bortezomib (Velcade), cisplatin and radiotherapy for advanced head and neck cancer ASCO January, 2008
8. A phase I trial of the combination of the anti-angiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies ASCO January, 2008
9. Value of FDG-PET for detecting metastatic lesions in head and neck cancer (abstr. #6047 ASCO January, 2008
10. Associations between radiation doses to pharyngeal regions and severe late toxicity in patients treated with concurrent chemoradiotherapy – an RTOG analysis ASTRO January, 2007
11. A phase I trial using the proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for high grade gliomas ASCO January, 2007
12. Quality of Life (QOL) supercedes the classic predictors of survival in locally advanced non-small cell lung cancer (NSCLC): An analysis of Radiation Therapy Oncology Group (RTOG) 9801. ASTRO January, 2007
13. Phase II randomized trial of surgery followed by chemoradiation plus cetuximab for high risk squamous cell carcinoma of the head and neck (RTOG 0234). ASTRO January, 2007
14. Is intensity modulated radiation therapy superior to 3D conformal radiotherapy for locally advanced head and neck cancer treated with aggressive concurrent cisplatin/taxane chemotherapy? ASTRO January, 2007
15. A phase I trial of patupilone (epothilone B) and concurrent radiotherapy for CNS malignancies ASTRO January, 2007
16. Randomized trial of amifostine in locally advanced NSCLC patients receiving chemotherapy and hyperfractionated radiation (HRT): Long-term survival results of RTOG 98-01 ASCO January, 2007
17. Utility of FDG-PET scans in staging and prediction of outcome in head and neck cancer ASTRO January, 2006
18. Pre-treatment and treatment related risk factors for Severe Late Toxicity after Chemo-RT for Head and Neck Cancer: An RTOG Analysis ASCO January, 2006
19. Phase I: Update of Weekly docetaxel, cisplatin, daily celecoxib, concurrent radiotherapy in advanced head and neck cancer (P015). annual meeting of the American Head and Neck Society. January, 2006
20. Improved hearing preservation with deescalated dose of fractionated stereotactic radiotherapy (SRT) in patients with acoustic schwannomas: 50.4 Gy vs. 46.8 Gy ASTRO January, 2006
21. Randomized trial of amifostine in locally advanced NSCLC patients receiving chemotherapy and hyperfractionated radiation: Long-term results of RTOG 98-01 ASTRO January, 2006
22. Risk of cardiac and pulmonary death after post-operative radiotherapy (PORT) for NSCLC: Analysis of the SEER program ASCO January, 2006
23. Higher BED is associated with improved local-regional control and survival for NSCLC treated with chemoradiation: An RTOG Analysis ASTRO January, 2005
24. A Phase I study of Gefitinib (Iressa) in combination with hypofractionated thoracic radiation therapy (HRT) with stereotactic body fram (SBF) immobilization in patients with advanced NSCLC: Preliminary results on the first dose level. ASTRO January, 2005
25. What is the meaning of local control after chemoradiotherapy for locally advanced NSCLC? An RTOG analysis annual meeting of the International Association for the Study of Lung Cancer January, 2005
26. Phase I study of weekly Docetaxel, cisplatin with daily celecoxib and concurrent radiotherapy for patients with locally advanced head and neck cancer. ASCO January, 2005
27. Impact of overall treatment time during concurrent chemoradiotherapy for locally advanced NSCLC: an RTOG secondary analysis. annual meeting of the American Society of Clinical Oncology (ASCO) January, 2005
28. Neck dissection (without primary tumor resection) followed by concurrent chemoradiation for stage IV oropharynx carcinoma ASCO January, 2005
29. A randomized phase III trial to assess the effect of erythropoietin on local-regional control and survival in anemic head and neck cancer patients: Initial report of RTOG 99-03 ASTRO January, 2004
30. Unexpected excessive toxicity in a pilot study of accelerated conformal radiotherapy with concurrent chemotherapy for stage III NSCLC ASCO January, 2004
31. RTOG 9705, a phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIA non-small cell lung cancer (NSCLC) patients - promising long term survival results ASTRO January, 2003
32. Amifostine as mucosal protectant in patients with locally advanced non-small cell lung cancer (NSCLC) receiving intensive chemotherapy and thoracic radiotherapy (RT): results of the Radiation Therapy Oncology Group (RTOG) 98-01 study ASTRO January, 2003
33. “Cisplatin dose delivery and survival in concurrent chemoradiation for stage III NSCLC: An RTOG secondary analysis.” Combined Modality Scientific Session at the biannual meeting of the International Association for the Study of Lung cancer January, 2003
34. Signaling pathways in NSCLC as a predictor of outcome and response to therapy. AACR January, 2003
35. Amelioration of radiation pulmonary fibrosis in a C57Bl murine model using antioxidant enzymes AACR January, 2003
36. The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years ASCO January, 2003
37. Phase III study of amifostine in patients with locally advanced non-small cell lung cancer (NSCLC) receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group (RTOG) 98-01 ASCO January, 2003
38. PEG-Catalase/PEG-SOD Mixture attenuates radiation-induced mouse lung fibrosis but not pneumonitis American Thoracic Society meeting January, 2003
39. Combined Modality Therapy for Locally Advanced Oropharyngeal Carcinoma: Final Results of a Phase II Study Using Induction and Concurrent Chemoradiation ASCO January, 2002
40. Phase I/II trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer ASCO January, 2002
41. Tumor Characteristics Obtained using FDG-PET Imaging in Lung Cancer for 3D Radiotherapy Annual meeting of the Society of Nuclear Medicine J Nucl Med January, 2002
42. Initial non-surgical treatment for T3/T4 head and neck squamous cell carcinoma (HNSCC) does not compromise ultimate local control: the role of planned pathologic restaging and early surgical salvage. ASCO January, 2002
43. Patterns of failure for resected advanced head & neck cancer treated by concurrent chemotherapy and radiation therapy: analysis of RTOG 95-01/Intergroup hase III trial. ASTRO January, 2002
44. Self-reported symptom distress during treatment for head and neck squamous cell carcinoma (HNSCC): concurrent chemoradiation (CRT) versus radiation therapy (RT) alone ASCO January, 2002
45. Association between pathologic response to neoadjuvant chemoradiotherapy and long-term survival for stage III non-small cell lung carcinoma (NSCLC) ASCO January, 2002
46. Postoperative concurrent radiochemotherapy in high-risk SCCA of the head and neck: Initial report of RTOG 9501/Intergroup Phase III trial (abstr. #903 ASCO January, 2002
47. Tumor characteristics obtained using FDG-PET Imaging in Lymphoma for 3D Radiation Therapy Annual meeting of the Society of Nuclear Medicine J Nucl Med January, 2002
48. Weekly carboplatin and paclitaxel concurrent with radiation therapy (RT) for locally advanced head and neck squamous cell carcinoma (HNSCC): preliminary results from the Hospital of the University of Pennsylvania (HUP) experience ASCO January, 2002
49. Relative risk of stroke in head and neck carcinoma patients treated with external cervical irradiation ASCO January, 2002
50. A secondary analysis of RTOG 86-10: does the extent of progression at the time of initiating salvage hormone therapy influence survival in patients with prostate cancer who failed initial treatment with irradiation? ASCO January, 2001
51. Phase II study of reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck: survival results ASCO January, 2001
52. A Phase I study of SPI-77 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer ASCO January, 2001
53. Tumor characteristics obtained using FDG-PET imaging in lung cancer and new strategies for 3D radiotherapy. the 43rd annual meeting of the American Association of Physics in Medicine January, 2001
54. Concurrent Chemoradiation for Locally Advanced NSCLC in the RTOG Experience: Effect of Overall Treatment Time ASTRO January, 2001
55. Immunoconjugates of Catalase Attenuate Radiation-Induced Pulmonary Fibrosis in C57Bl Mice. ASTRO January, 2001
56. Comparison of anatomic and metabolic tumor imaging in head and neck squamous cell cancer (HNSCC). ASTRO January, 2001
57. A phase III trial comparing whole-pelvic versus prostate only radiotherapy and neoadjuvant versus adjuvant total androgen suppression: preliminary analysis of radiation therapy oncology group (RTOG) 9413 ASTRO January, 2001
58. Phase II Study of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II and IIIA Non-Small Cell Lung Cancer (RTOG 97-05). ASTRO January, 2001
59. A Phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer ASTRO January, 2001
60. Optimizing supraclavicular coverage and lung sparing in the low anterior neck field. Proc. Radiological Society of North America meeting January, 2000
61. Pathologic response to preoperative chemoradiation worsens with anemia in non-small cell lung cancer (NSCLC) patients RSNA meeting January, 2000
62. Does clinical and/or imaging response to induction chemotherapy predict ultimate outcome in locally advanced oropharynx carcinoma? Analysis of a prospective phase II multimodality trial RSNA meeting January, 2000
63. Neoadjuvant hormone treatment does not compromise the benefits of subsequent androgen suppression with patients in prostate cancer who fail initial radiation therapy: A secondary analysis of the RTOG phase III trial 86-10 ASTRO January, 2000
64. Androgen ablation adjuvant to definitive radiotherapy in carcinoma of the prostate ASTRO January, 2000
65. RTOG protocol 92-02: A phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate ASTRO January, 2000
66. Phase I study of reirradiation (RRT) with concurrent hydroxyurea (HU) and 5-fluorouracil (FU) in patients with squamous cell cancer of the head and neck ASTRO January, 2000
67. Preliminary results of a Radiation Therapy Oncology Group trial (RTOG) 9705, a phase II study of postoperative adjuvant therapy in patients with completely reseted stage II and stage IIIA non-small cell lung cancer. the 9th World Conference on Lung Cancer January, 2000
68. The utility of positron emission tomography (PET) scanning in the workup of head and neck cancer RSNA meeting January, 2000
69. The utility of positron emission tomography (PET) scanning in the workup of head and neck cancer. Proc 5th Int Conf on Head and Neck Cancer; 5th International Conference on Head and Neck Cancer, January, 2000
70. Neck management in an organ preservation trial for locally advanced oropharynx carcinoma. Proc 5th Int Conf on Head and Neck Cancer January, 2000
71. Early results of a phase II trial of chemoradiotherapy for lcoally advanced oropharynx carcinoma: important prognostic value of T-stage 5th Int Conf on Head and Neck Cancer January, 2000
72. Nasopharyngeal carcinoma treated with external radiotherapy (XRT), brachytherapy, and concurrent and adjuvant chemotherapy 5th International Conference on Head and Neck Cancer January, 2000
73. Treatment of advanced squamous cell carcinoma of the head and neck (SCCHN) with altered fractionation radiation therapy (AFRT) versus chemoradiation (CRT). 5th International Conference on Head and Neck Cancer January, 2000
74. Aggressive cutaneous malignancies: implications for management of the fgacial nerve. International Conference on Head and Neck Cancer January, 2000
75. Cisplatin (P), etoposide (E), paclitaxel (T) and concurrent hyperfractionated thoracic radiotherapy (TRT) for patients (pts) with limited disease (LD) small cell lung cancer (SCLC): preliminary results of RTOG 96-09 (abstr #1917) annual meeting of the American Society of Clinical Oncology January, 2000
76. A Phase I/II trial of accelerated radiation therapy and concurrent 96-hour infusional paclitaxel for unresectable squamous cell carcinoma of the head and neck (abstr #1676). annual meeting of the American Society of Clinical Oncology. January, 2000
77. Induction chemotherapy for T4 oropharynx carcinoma in a prospective multimodality phase II trial: ‘partial’ response is not enough (abstr #1669) annual meeting of the American Society of Clinical Oncology. January, 2000
78. Risk of brain metastases is higher with delayed thoracic irradiation for locally advanced non-small cell lung carcinoma (NSCLC) (abstr #1943). annual meeting of the American Society of Clinical Oncology January, 2000
79. Neoadjuvant paclitaxel-carboplatin plus irradiation (XRT) improves resectability and local-regional control over neoadjuvant paclitaxel alone for stage IIIA non-small cell lung carcinoma (NSCLC) annual meeting of the American Society of Clinical Oncology January, 2000
80. RTOG protocol 92-02: a phase III trial of the use of long term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate (abstr #1284) annual meeting of the American Society of Clinical Oncology January, 2000
81. A comparison of radiation treatment techniques for carcinoma of the nasopharynx (NPC) annual meeting of the American Radium Society. January, 2000
82. The risk of brain metastases after definitive chemoradiation for locally advanced non-small cell lung carcinoma American Radium Society January, 2000
83. Organ preservation for locally advanced oropharyngeal carcinoma: interim analysis of a University of Pennsylvania multimodality phase II trial American Head and Neck Society meeting January, 1999
84. A phase III study evaluating the efficacy of conventional radiation therapy with or without recombinant B-interferon for patients with locally advanced non-small cell lung cancer and poor prognostic characteristics (RTOG 93-04). American Society of Therapeutic Radiology and Oncology January, 1999
85. Long-term outcome for patients with locally advanced non-metastatic prostate cancer treated with adjuvant hormones and radiation therapy versus radiation therapy alone: subset analysis of RTOG 85-31 and 86-10. American Society of Therapeutic Radiology and Oncology January, 1999
86. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. American Society of Therapeutic Radiology and Oncology January, 1999
87. Chemoradiation with or without surgery for stage IIIA non-small cell lung carcinoma (NSCLC): a comparison of survival and patterns of failure American Society of Therapeutic Radiology and Oncology January, 1999
88. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen deprivation following standard radiation therapy for unfavorable prognosis carcinoma of the prostate American Society of Clinical Oncology (ASCO) meeting January, 1999
89. Postoperative radiotherapy for non-small cell lung carcinoma does not lead to an excess rate of intercurrent death the American Society of Clinical Oncology (ASCO) meeting January, 1999
90. Preliminary toxicity report of a Phase II trial of organ preservation multimodality therapy for locally advanced oropharyngeal carcinoma. American Society of Clinical Oncology (ASCO) meeting January, 1999
91. Dose escalating 7-week continuous infusion paclitaxel with concurrent once-daily radiation therapy for locally advanced squamous carcinoma of the head and neck. American Society of Clinical Oncology January, 1999
92. Neoadjuvant chemoradiotherapy with carboplatin/paclitaxel prior to surgery for IIIA non-small cell lung carcinoma (NSCLC) -- Preliminary experience of the University of Pennsylvania American Radium Society Annual Meeting January, 1999
93. The importance of the “treatment package” time in surgery and postoperative radiotherapy for squamous cell carcinoma of the head and neck: The University of Pennsylvania Experience American Radium Society Annual Meeting January, 1999
94. Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of Androgen Deprivation before and during Radiotherapy in Locally Advanced Carcinoma of the Prostate American Society of Therapeutic Radiology and Oncology (ASTRO) meeting January, 1998
95. Risk factors for relapse and poor survival following postoperative radiation therapy for non-small cell lung cancer Radiological Society of North America (RSNA) meeting January, 1998
96. Are patients with supraclavicular node metastases in non-small cell lung cancer curable? -- an analysis of the Radiation Therapy Oncology Group (RTOG) experience American Society of Therapeutic Radiology and Oncology (ASTRO) meeting January, 1998
97. A Comparison of Altered Fractionation Radiation Therapy vs. Chemoradiation for Unresectable Squamous Cell Carcinoma of the Head and Neck. American Society of Clinical Oncology January, 1998
98. A Phase I Trial of 96-hour Taxol Infusion plus Accelerated Radiotherapy for Unresectable Head and Neck Cancer American Society of Clinical Oncology meeting January, 1998
99. Phase III Radiation Therapy Oncology Group (RTOG) Trial of Androgen Depravation before and during Radiotherapy in Locally Advanced Carcinoma of the Prostate American Society of Clinical Oncology meeting January, 1998
100. The Efficacy of Postoperative Radiotherapy for Non-small Cell Lung Carcinoma (NSCLC) Resected with Positive Margins Proc. of the American Radium Society January, 1998
101. Does Pretreatment Hemoglobin Level Affect Outcome in Patients with T1 Glottic Cancer American Radium Society January, 1997
102. The Use of Positron Emission Tomography Imaging with 2-18F-fluoro-2-deoxy-D-glucose to Distinguish Post-Radiation Effects from Local Recurrence in Head and Neck Cancer American Radium Society January, 1997
103. Postoperative Radiotherapy after Wedge Resection of Non-small Cell Lung Carcinoma. American Society of Therapeutic Radiology and Oncology meeting January, 1997
104. Utility of Gastrostomy Tubes for Patients Receiving Intensive Irradiation to the Head and Neck Proc. American Society of Clinical Oncology January, 1997
105. Distinguishing Local Tumor Recurrence from Post-radiation Effects in Head and Neck Cancer using PET-FDG Imaging Proc. American Society of Clinical Oncology January, 1997
106. Does Pretreatment Hemoglobin Level Affect Outcome in Patients with T1 Glottic Cancer? Proc. American Society of Therapeutic Radiology and Oncology January, 1997
107. Combined Surgery and Postoperative Radiotherapy for Carcinoma of the Base of Tongue Proc. 4th International Conference on Head and Neck Cancer January, 1996
108. Decreased Acute Toxicity by Midline Mucosa-sparing Blocks during Radiotherapy for Carcinoma of the Oropharynx, Oral Cavity and Nasopharynx Meeting of the Radiological Society of North America January, 1994
109. Inaccuracies in Using the Lumpectomy Scar for Planning Electron Boosts in Primary Breast Carcinoma Proc. American Society of Therapeutic Radiology and Oncology January, 1993



Site wide Speaking/Presenting-Abstract/Poster at Mtg

Presentation Event Month, Year
head and neck cancer-- Integrating Intensity- Modulated Radiation Therapy/Image-Guided Radiation Therapy and Systemic Therapy into a Combined Modality Therapeutic Strategy (M09) ASCO Annual'08 Meeting May, 2008
meet the professor sessions-- Integrating Intensity- Modulated Radiation Therapy/Image-Guided Radiation Therapy and Systemic Therapy into a Combined Modality Therapeutic Strategy (M09) ASCO Annual'08 Meeting May, 2008

4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.